12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AV0113: Preliminary Phase II data

Activartis reported preliminary data from the open-label, Austrian Phase II GBM-Vax trial in about 100 brain cancer patients aged 18-70 years showing that AV0113 administered into inguinal lymph nodes as an add-on to standard therapy with radiotherapy and Temodar temozolomide (switched to Avastin bevacizumab upon disease recurrence) missed the primary endpoint of improving mean PFS vs. standard therapy alone (243 vs. 226 days). The company said control of tumor growth through cancer immunotherapies is achieved by inflammation, thus resulting in greater edema and...

Read the full 413 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >